Dear customer, we would like to introduce our new products from April 2020 and hope you will find them interesting.
NEW miREIA KITS
|CAT. NO.||NAME||ASSAY FORMAT|
|RDM0039H||hsa-miR-100-5p||miREIA – miRNA enzyme immunoassay|
|RDM0035H||hsa-miR-192-5p||miREIA – miRNA enzyme immunoassay|
|RDM0040H||hsa-miR-203a-3p||miREIA – miRNA enzyme immunoassay|
|RDM0041H||hsa-miR- 625-5p||miREIA – miRNA enzyme immunoassay|
|RDM0042H||hsa-miR-5100||miREIA – miRNA enzyme immunoassay|
Featured product: hsa-miR-625-5p miREIA
miR-625 has been found in various tumors, and it also exhibits diverse functions in cardiovascular diseases and pulmonary diseases.
- responsible for the regulation of metastasis in gastric tumor cells
- knockdown of RHPN1-AS1 inhibited the proliferation, migration and invasion activity of glioma cells via regulating miR-625-5p/REG3A expression
- regulated PKM2 expression on mRNA and protein level in melanoma cells (MC)
- negative relationship between miR-625-5p and PKM2 expression in clinical melanoma samples suggesting miR-625-5p/PKM2 plays a role in MC glucose metabolism
- negative regulator of cardiac hypertrophy
- inhibited cardiac hypertrophy through targeting STAT3 and CaMKII. miR-625-5p directly targeted CaMKII and inhibited its expression
- attenuated Ang II–induced cardiac hypertrophy through CaMKII/STAT3
- expression levels of miR-421, miR-1233-3p and miR-625-5p are lower in TOF patients with symptomatic right heart failure
- downregulation was confirmed in aortic valve stenosis as a major cause of morbidity and mortality
- inhibitor of asthma airway inflammation in human bronchial epithelial cells by targeting AKT2
- downregulated in the asthma
- overexpression inhibited interleukin-6 (IL-6) and tumor necrosis factor α (TNFα) secretion in 16HBECs
See more about hsa-miR-625-5p miREIA
For this and more BioVendor miREIA kits, please visit www.biovendor.com/mirna.
|CAT. NO.||SPECIES||NAME||ASSAY FORMAT|
|RAI009R||Human||Anti-SARS-CoV-2 S1RBD IgG ELISA||ELISA|
|G61RHA20||Biocredit Covid-19 Ag Detection Kit||Immunochromatography rapid test|
|RBG19001R||Human||Brain-derived Neurotrophic Factor (BDNF) ELISA||Sandwich ELISA|
|41A227||Human||Positive control: Humanized IgG Monoclonal Antibody against SARS-CoV-2 Nucleocapsid Protein (NP)||Control Set|
|Coming soon||Human||Positive control: Humanized IgM Monoclonal Antibody against SARS-CoV-2 Nucleocapsid Protein (NP)||Control Set|
|Coming soon||Human||Positive control: Humanized IgG Monoclonal Antibody against SARS-CoV-2 S1RBD||Control Set|
|RGP028R||Human||Interleukin-6R (CD126) ELISA||Sandwich ELISA|
|466175||Nanopia KL-6 Reagent 1 ELISA||Immunoturbidimetric assay|
|466199||Nanopia KL-6 Reagent 2 ELISA||Immunoturbidimetric assay|
|1N38C2||Human||Rapid 2019-nCoV IgG/IgM Combo Test||Immunochromatography rapid test|
|41A225||Human||SARS-CoV-2 NP Ab ELISA||ELISA|
|41A222||Human||SARS-CoV-2 NP IgG ELISA||ELISA|
|41A224||Human||SARS-CoV-2 NP IgM ELISA||ELISA|
|41A228||Human||SARS-CoV-2 Nucleocapsid protein (NP) High-sensitivity Quantitative||ELISA|
Featured Product: Anti-SARS-CoV-2 Antibody and Antigen Detection ELISA Kits
COVID-19 is pandemic as declared by the World Health Organization (WHO). As the disease outbreak has spread within the population, serologic assays complementary to the molecular diagnostic methods are urgently needed. Validated serologic assays are necessary for contact tracing, identifying the viral reservoir, and epidemiologic studies.
Patients are developing antibodies from two to about fifteen days after developing symptoms. The typical reaction, similar to many other pathogens, is: first, a flush of IgM, a generic type of antibody, followed later by the longer-lasting and more-specific IgG antibodies. It has been published that combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19, even in the early phase of 1-week since onset. Moreover, a higher titer of Ab was independently associated with a worse clinical classification.
Despite the advantages of rapid tests (simplicity, fast result obtaining), validated ELISA tests represent the gold standard in serology.
Anti-NP Ab, IgM and IgG ELISAs
The nucleocapsid protein (NP) is the most abundant viral protein and the anti-NP antibodies are the earliest and the most predominant antibodies detectable in the patient’s blood samples after coronavirus infection. Among the total Ab, IgM and IgG specific assays, the anti-NP Ab provides the best clinical sensitivity while the anti-NP IgM and NP IgG allow distinguishing specifically the IgM or IgG phase of the immune response.
See more about Anti-NP Ab, IgM and IgG ELISAs
Anti-S1RBD IgG ELISA
For coronaviruses, the most divergent protein is the spike protein. S1 polypeptide contains a receptor-binding domain (S1RBD) crucial for the specific recognition and interaction with the human receptor ACE2, which is the first and the most essential step for the virus infection. The spike protein is the main antigen that elicits neutralizing antibodies, as this protein is the sole protein on the viral surface that is responsible for entry into the host cell.
See more about Anti-S1RBD IgG ELISA
NP antigen quantification ELISA
The highly sensitive assay can recognize and quantify recombinant and native SARS-CoV-2 NP in serum or other samples with an excellent sensitivity of 5 pg/ml.
See more about NP antigen quantification ELISA
|RP1791121050||Human||ACE2 (18-615), Human Recombinant (CHO cells)||0.05 mg||CHO cells|
|RP1791122050||Human||ACE2 (19-740), Human Recombinant (CHO cells)||0.05 mg||CHO cells|
|RD173035100||Human||Connective Tissue Growth Factor||0.1 mg||E.coli Tag free|
|RD172349100||Human||MxA Protein||0.1 mg||E. coli|
|RP9720150050||SARS||SARS-CoV-2 (2019-nCoV) Nucleocapsid Mosaic Protein||0.05 mg||E. coli|
|RP9720150250||SARS||SARS-CoV-2 (2019-nCoV) Nucleocapsid Mosaic Protein||0.25 mg||E. coli|
|RP9720151000||SARS||SARS-CoV-2 (2019-nCoV) Nucleocapsid Mosaic Protein||1 mg||E. coli|
|RP9720130050||SARS||SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein||0.05 mg||E. coli|
|RP9720130250||SARS||SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein||0.25 mg||E. coli|
|RP9720131000||SARS||SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein||1 mg||E. coli|
|RP9720110050||SARS||SARS-CoV-2 (2019-nCoV) Spike Glycoprotein-S1 Protein||0.05 mg||HEK293|
|RP9720110150||SARS||SARS-CoV-2 (2019-nCoV) Spike Glycoprotein-S1 Protein||0.15 mg||HEK293|
|RP9720110250||SARS||SARS-CoV-2 (2019-nCoV) Spike Glycoprotein-S1 Protein||0.25 mg||HEK293|
|RP9720120050||SARS||SARS-CoV-2 (2019-nCoV) Spike Glycoprotein-S2 Protein||0.05 mg||HEK293|
|RP9720120150||SARS||SARS-CoV-2 (2019-nCoV) Spike Glycoprotein-S2 Protein||0.15 mg||HEK293|
|RP9720120250||SARS||SARS-CoV-2 (2019-nCoV) Spike Glycoprotein-S2 Protein||0.25 mg||HEK293|
|RP9720140050||SARS||SARS-CoV-2 (2019-nCoV) Spike-E-M Mosaic Protein||0.05 mg||E. coli|
|RP9720140250||SARS||SARS-CoV-2 (2019-nCoV) Spike-E-M Mosaic Protein||0.25 mg||E. coli|
|RP9720141000||SARS||SARS-CoV-2 (2019-nCoV) Spike-E-M Mosaic Protein||1 mg||E. coli|
|RI973598100||SARS||SARS-CoV-2 Nucleocapsid protein (NP)||0.1 mg||E. coli|
|RI973599100||SARS||SARS-CoV-2 Spike Protein S1 Receptor-Binding Domain (S1RBD)||0.1 mg||E. coli|
Featured product: SARS-CoV-2 and ACE2 Recombinant Proteins
Coronaviruses (CoVs), within the order Nidovirales, are enveloped, single-strand, positive-sense RNA viruses with a large genome of approximately 30 kbp in length. The new virus is named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with the resulting disease known as coronavirus disease 2019 (COVID-19).
SARS-CoV-2 contains four structural proteins: Spike (S) protein consisting of two subunits, S1 and S2, envelope (E) protein, membrane (M) protein, and nucleocapsid (N) protein. BioVendor offers a broad spectrum and variants of recombinant SARS-CoV-2 proteins.
Besides the coronavirus proteins, human ACE2 (Angiotensin-converting enzyme 2) enzyme/receptor presented on the cell surface of many organs (e.g. intestines, arteries, lungs, heart and kidney) is a key protein in developing COVID-19 infection in the human body. SARS-CoV-2 binds the cellular receptor ACE2 through the receptor-binding domain (RBD) of the S1 subunit of the coronavirus Spike protein (S). This interaction enables the virus to enter the host cell.
See more about SARS-CoV-2 and ACE2 Recombinant Proteins
NEW PCR KITS / ENZYMES / REAGENTS
|NFIH001||Human||A*STAR Fortitude 2.0 COVID-19 Real-Time RT-PCR Test||RT-qPCR||200 tests (kit)|
|RR-0479-02||Human||Liferiver Novel Coronavirus (2019-nCoV) Real Time Multiplex RT-PCR Kit||RT-qPCR||25 tests (kit)|
|DHUV02313||Human||ViroReal® Kit SARS-CoV-2 & SARS||RT-qPCR||100 rxns|
|DHUV02313x5||Human||ViroReal® Kit SARS-CoV-2 & SARS||RT-qPCR||500 rxns|
|DHUV02313x50||Human||ViroReal® Kit SARS-CoV-2 & SARS||RT-qPCR||5000 rxns|
Featured product: RT-qPCR: ViroReal® Kit SARS-CoV-2 & SARS
A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic of COVID-19. Molecular diagnostic tests based on reverse transcription real-time PCR (RT-PCR) were rapidly developed and represent the frontline diagnostic tool and established confirmation method.
ViroReal® Kit SARS-CoV-2 & SARS detects the nucleocapsid protein gene (N gene) of SARS-CoV-2 as well as SARS-CoV and SARS-related coronavirus. ViroReal® Kit SARS-CoV-2 & SARS is intended to cover possible future changes in the virus sequence, therefore a highly conserved region in all SARS coronavirus clusters of the N gene was chosen as the target region. This approach allows universal detection of all so far known SARS-CoV strains including SARS-CoV-2 and SARS-like CoV without discriminating between strains. The primer and probe design chosen is not identical to the WHO design.
An internal RNA positive control (RNA IPC) is detected in Cy5 channel and is used as RNA extraction as well as RT-PCR inhibition control. The target for the RNA IPC is extracted with the sample.
The advantage of the assay design is an easy interpretation of single-gene determination, targeting the conserved region of the N gene ensures high resistance to expected virus mutations.
See more about RT-qPCR: ViroReal® Kit SARS-CoV-2 & SARS
COVID-19 Associated Assays & Reagents | BioVendor Webinar #2
As a leading developer and manufacturer of IVD and Life Science products, BioVendor is committed to contribute to manage the spread of COVID-19 and to accelerate the research related to the SARS-CoV-2 virus. We share information about our assays and reagents and explain what is their utility in the context of COVID-19 outbreak. From diagnosis through research to diagnostic device development. We are looking forward to the special issue of BioVendor webinar with the BioVendor team.
Key points covered in this webinar:
- COVID-19: Diagnosis
- COVID-19: Prognosis
- COVID-19: Therapy monitoring / Disease progression
- Research and assay development reagents
COVID-19 Associated Assays & Reagents
BioVendor News Let's keep in touch!
Click to sign up for our newsletter to receive regular updates: NEWLETTER